1lpe › Citations

Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E.

Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA
Science 252 1817-22 (1991)
Cited: 372 times
EuropePMC logo PMID: 2063194

Abstract

Human apolipoprotein E, a blood plasma protein, mediates the transport and uptake of cholesterol and lipid by way of its high affinity interaction with different cellular receptors, including the low-density lipoprotein (LDL) receptor. The three-dimensional structure of the LDL receptor-binding domain of apoE has been determined at 2.5 angstrom resolution by x-ray crystallography. The protein forms an unusually elongated (65 angstroms) four-helix bundle, with the helices apparently stabilized by a tightly packed hydrophobic core that includes leucine zipper-type interactions and by numerous salt bridges on the mostly charged surface. Basic amino acids important for LDL receptor binding are clustered into a surface patch on one long helix. This structure provides the basis for understanding the behavior of naturally occurring mutants that can lead to atherosclerosis.

Reviews - 1lpe mentioned but not cited (5)

  1. Apolipoprotein E: from lipid transport to neurobiology. Hauser PS, Narayanaswami V, Ryan RO. Prog Lipid Res 50 62-74 (2011)
  2. Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Chen Y, Strickland MR, Soranno A, Holtzman DM. Neuron 109 205-221 (2021)
  3. Impact of apolipoprotein E on Alzheimer's disease. Hauser PS, Ryan RO. Curr Alzheimer Res 10 809-817 (2013)
  4. The helix bundle: a reversible lipid binding motif. Narayanaswami V, Kiss RS, Weers PM. Comp Biochem Physiol A Mol Integr Physiol 155 123-133 (2010)
  5. Interpretable artificial intelligence and exascale molecular dynamics simulations to reveal kinetics: Applications to Alzheimer's disease. Martin W, Sheynkman G, Lightstone FC, Nussinov R, Cheng F. Curr Opin Struct Biol 72 103-113 (2022)

Articles - 1lpe mentioned but not cited (11)

  1. Packing helices in proteins by global optimization of a potential energy function. Nanias M, Chinchio M, Pillardy J, Ripoll DR, Scheraga HA. Proc Natl Acad Sci U S A 100 1706-1710 (2003)
  2. In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: misfolding induced by frustration of the salt bridge network. Luo J, Maréchal JD, Wärmländer S, Gräslund A, Perálvarez-Marín A. PLoS Comput Biol 6 e1000663 (2010)
  3. Rationally selected basis proteins: a new approach to selecting proteins for spectroscopic secondary structure analysis. Oberg KA, Ruysschaert JM, Goormaghtigh E. Protein Sci 12 2015-2031 (2003)
  4. Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy. Georgiadou D, Stamatakis K, Efthimiadou EK, Kordas G, Gantz D, Chroni A, Stratikos E. J Lipid Res 54 164-176 (2013)
  5. Structural and functional characterization of human apolipoprotein E 72-166 peptides in both aqueous and lipid environments. Hsieh YH, Chou CY. J Biomed Sci 18 4 (2011)
  6. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. PLoS One 6 e27037 (2011)
  7. MARTINI bead form factors for the analysis of time-resolved X-ray scattering of proteins. Niebling S, Björling A, Westenhoff S. J Appl Crystallogr 47 1190-1198 (2014)
  8. Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy. Katsarou M, Stratikos E, Chroni A. J Lipid Res 59 2339-2348 (2018)
  9. The structure of human apolipoprotein C-1 in four different crystal forms. McPherson A, Larson SB. J Lipid Res 60 400-411 (2019)
  10. Iterative assembly of helical proteins by optimal hydrophobic packing. Wu GA, Coutsias EA, Dill KA. Structure 16 1257-1266 (2008)
  11. Analogs of LDL Receptor Ligand Motifs in Dengue Envelope and Capsid Proteins as Potential Codes for Cell Entry. Guevara J, Romo J, McWhorter T, Guevara NV. J Viruses 2015 646303 (2015)


Reviews citing this publication (78)

  1. Apolipoprotein E: far more than a lipid transport protein. Mahley RW, Rall SC. Annu Rev Genomics Hum Genet 1 507-537 (2000)
  2. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Mahley RW, Weisgraber KH, Huang Y. Proc Natl Acad Sci U S A 103 5644-5651 (2006)
  3. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Nat Rev Neurol 15 501-518 (2019)
  4. Apolipoprotein E structure: insights into function. Hatters DM, Peters-Libeu CA, Weisgraber KH. Trends Biochem Sci 31 445-454 (2006)
  5. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Kanekiyo T, Xu H, Bu G. Neuron 81 740-754 (2014)
  6. The life of lipid droplets. Walther TC, Farese RV. Biochim Biophys Acta 1791 459-466 (2009)
  7. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Mahley RW, Huang Y. Curr Opin Lipidol 10 207-217 (1999)
  8. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. Mahley RW. J Mol Med (Berl) 94 739-746 (2016)
  9. The mammalian low-density lipoprotein receptor family. Hussain MM, Strickland DK, Bakillah A. Annu Rev Nutr 19 141-172 (1999)
  10. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala-Korpela M. Biochim Biophys Acta 1488 189-210 (2000)
  11. Structure and physiologic function of the low-density lipoprotein receptor. Jeon H, Blacklow SC. Annu Rev Biochem 74 535-562 (2005)
  12. The key role of apolipoprotein E in atherosclerosis. Greenow K, Pearce NJ, Ramji DP. J Mol Med (Berl) 83 329-342 (2005)
  13. Structural models of human apolipoprotein A-I: a critical analysis and review. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Biochim Biophys Acta 1531 4-46 (2001)
  14. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. Huang Y, Weisgraber KH, Mucke L, Mahley RW. J Mol Neurosci 23 189-204 (2004)
  15. Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Saito H, Lund-Katz S, Phillips MC. Prog Lipid Res 43 350-380 (2004)
  16. High density lipoprotein structure-function and role in reverse cholesterol transport. Lund-Katz S, Phillips MC. Subcell Biochem 51 183-227 (2010)
  17. Molecular basis of exchangeable apolipoprotein function. Narayanaswami V, Ryan RO. Biochim Biophys Acta 1483 15-36 (2000)
  18. Antifreeze proteins. Davies PL, Sykes BD. Curr Opin Struct Biol 7 828-834 (1997)
  19. Lipid transport biochemistry and its role in energy production. Ryan RO, van der Horst DJ. Annu Rev Entomol 45 233-260 (2000)
  20. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. Adv Drug Deliv Rev 47 251-276 (2001)
  21. New insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolism. Phillips MC. J Lipid Res 54 2034-2048 (2013)
  22. Viral cell recognition and entry. Rossmann MG. Protein Sci 3 1712-1725 (1994)
  23. Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features. Tudorache IF, Trusca VG, Gafencu AV. Comput Struct Biotechnol J 15 359-365 (2017)
  24. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. Zhong N, Weisgraber KH. J Biol Chem 284 6027-6031 (2009)
  25. The role of apolipoprotein E genetic variants in lipoprotein disorders. Rall SC, Mahley RW. J Intern Med 231 653-659 (1992)
  26. The LDL receptor: how acid pulls the trigger. Beglova N, Blacklow SC. Trends Biochem Sci 30 309-317 (2005)
  27. The Role of APOE and TREM2 in Alzheimer's Disease-Current Understanding and Perspectives. Wolfe CM, Fitz NF, Nam KN, Lefterov I, Koldamova R. Int J Mol Sci 20 E81 (2018)
  28. Insect adipokinetic hormones: release and integration of flight energy metabolism. Van der Horst DJ. Comp Biochem Physiol B Biochem Mol Biol 136 217-226 (2003)
  29. The vascular contribution to Alzheimer's disease. Altman R, Rutledge JC. Clin Sci (Lond) 119 407-421 (2010)
  30. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM. Hum Mutat 4 178-194 (1994)
  31. Three-dimensional models of HDL apoA-I: implications for its assembly and function. Thomas MJ, Bhat S, Sorci-Thomas MG. J Lipid Res 49 1875-1883 (2008)
  32. Pyrene: a probe to study protein conformation and conformational changes. Bains G, Patel AB, Narayanaswami V. Molecules 16 7909-7935 (2011)
  33. Structural models of human apolipoprotein A-I. Brouillette CG, Anantharamaiah GM. Biochim Biophys Acta 1256 103-129 (1995)
  34. APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics. Husain MA, Laurent B, Plourde M. Front Neurosci 15 630502 (2021)
  35. Hemolymph lipid transport. Blacklock BJ, Ryan RO. Insect Biochem Mol Biol 24 855-873 (1994)
  36. Alternative lipid mobilization: the insect shuttle system. van der Horst DJ, van Hoof D, van Marrewijk WJ, Rodenburg KW. Mol Cell Biochem 239 113-119 (2002)
  37. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. Mol Neurodegener 17 72 (2022)
  38. The Genetic Variability of APOE in Different Human Populations and Its Implications for Longevity. Abondio P, Sazzini M, Garagnani P, Boattini A, Monti D, Franceschi C, Luiselli D, Giuliani C. Genes (Basel) 10 E222 (2019)
  39. Apolipoprotein structural organization in high density lipoproteins: belts, bundles, hinges and hairpins. Davidson WS, Silva RA. Curr Opin Lipidol 16 295-300 (2005)
  40. Evolution of the diverse antifreeze proteins. Cheng CH. Curr Opin Genet Dev 8 715-720 (1998)
  41. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Pharmacogenomics J 7 10-28 (2007)
  42. The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer's Disease Cohorts. Heffernan AL, Chidgey C, Peng P, Masters CL, Roberts BR. J Mol Neurosci 60 316-324 (2016)
  43. Adipose Triglyceride Lipase Regulation: An Overview. Cerk IK, Wechselberger L, Oberer M. Curr Protein Pept Sci 19 221-233 (2018)
  44. ApoE Lipidation as a Therapeutic Target in Alzheimer's Disease. Lanfranco MF, Ng CA, Rebeck GW. Int J Mol Sci 21 E6336 (2020)
  45. Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Poirier J, Minnich A, Davignon J. Ann Med 27 663-670 (1995)
  46. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Bolanos-Garcia VM, Miguel RN. Prog Biophys Mol Biol 83 47-68 (2003)
  47. The cytoplasmic face of cell contact sites. Pokutta S, Weis WI. Curr Opin Struct Biol 12 255-262 (2002)
  48. The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update. Mahoney-Sanchez L, Belaidi AA, Bush AI, Ayton S. J Mol Neurosci 60 325-335 (2016)
  49. APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. Wolf AB, Caselli RJ, Reiman EM, Valla J. Neurobiol Aging 34 1007-1017 (2013)
  50. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Blacklow SC. Curr Opin Struct Biol 17 419-426 (2007)
  51. Accumulation of high-value lipids in single-cell microorganisms: a mechanistic approach and future perspectives. Garay LA, Boundy-Mills KL, German JB. J Agric Food Chem 62 2709-2727 (2014)
  52. Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. Calandra S, Tarugi P, Speedy HE, Dean AF, Bertolini S, Shoulders CC. J Lipid Res 52 1885-1926 (2011)
  53. The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Coppens I, Courtoy PJ. Annu Rev Microbiol 54 129-156 (2000)
  54. Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights. Das M, Gursky O. Adv Exp Med Biol 855 175-211 (2015)
  55. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Wong K, Ryan RO. Curr Opin Lipidol 18 319-324 (2007)
  56. Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders. Gamache J, Yun Y, Chiba-Falek O. Dis Model Mech 13 dmm045211 (2020)
  57. NMR studies of lipoprotein structure. Cushley RJ, Okon M. Annu Rev Biophys Biomol Struct 31 177-206 (2002)
  58. Apolipoprotein structure and dynamics. Gursky O. Curr Opin Lipidol 16 287-294 (2005)
  59. Recombinant apolipoproteins for the treatment of vascular diseases. Sirtori CR, Calabresi L, Franceschini G. Atherosclerosis 142 29-40 (1999)
  60. Apolipoprotein E mimetics and cholesterol-lowering properties. Sharifov OF, Nayyar G, Garber DW, Handattu SP, Mishra VK, Goldberg D, Anantharamaiah GM, Gupta H. Am J Cardiovasc Drugs 11 371-381 (2011)
  61. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Gianturco SH, Bradley WA. Clin Cardiol 22 II7-14 (1999)
  62. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia. Matsunaga A, Saito T. Clin Exp Nephrol 18 220-224 (2014)
  63. The significance of apolipoprotein E structure to the metabolism of plasma triglyceride-rich lipoproteins. Dergunov AD, Rosseneu M. Biol Chem Hoppe Seyler 375 485-495 (1994)
  64. How the lipid-free structure of the N-terminal truncated human apoA-I converts to the lipid-bound form: new insights from NMR and X-ray structural comparison. Wang G. FEBS Lett 529 157-161 (2002)
  65. Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging. Almer G, Mangge H, Zimmer A, Prassl R. Curr Med Chem 22 3631-3651 (2015)
  66. Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents. Chuang ST, Cruz S, Narayanaswami V. Nanomaterials (Basel) 10 E906 (2020)
  67. The Role of ApoE in HCV Infection and Comorbidity. Gong Y, Cun W. Int J Mol Sci 20 E2037 (2019)
  68. Lipoproteins in the Central Nervous System: From Biology to Pathobiology. Raulin AC, Martens YA, Bu G. Annu Rev Biochem 91 731-759 (2022)
  69. The Role of ApoE Expression and Variability of Its Glycosylation in Human Reproductive Health in the Light of Current Information. Kacperczyk M, Kmieciak A, Kratz EM. Int J Mol Sci 22 7197 (2021)
  70. CETP and exchangeable apoproteins: common features in lipid binding activity. Bolaños-García VM, Soriano-García M, Mas-Oliva J. Mol Cell Biochem 175 1-10 (1997)
  71. Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: review and hypothesis. Dergunov AD, Visvikis-Siest S, Siest G. Vascul Pharmacol 48 70-75 (2008)
  72. Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease? Vecchio FL, Bisceglia P, Imbimbo BP, Lozupone M, Latino RR, Resta E, Leone M, Solfrizzi V, Greco A, Daniele A, Watling M, Panza F, Seripa D. Ther Adv Chronic Dis 13 20406223221081605 (2022)
  73. S-phase DNA damage checkpoint in budding yeast. Foiani M, Ferrari M, Liberi G, Lopes M, Lucca C, Marini F, Pellicioli A, Muzi Falconi M, Plevani P. Biol Chem 379 1019-1023 (1998)
  74. Oxidative protein labeling with analysis by mass spectrometry for the study of structure, folding, and dynamics. Liuni P, Zhu S, Wilson DJ. Antioxid Redox Signal 21 497-510 (2014)
  75. Apolipoprotein E and viral infection: Risks and Mechanisms. Chen F, Ke Q, Wei W, Cui L, Wang Y. Mol Ther Nucleic Acids 33 529-542 (2023)
  76. Old and new players in the lipoprotein system. Zannis VI, Cohen J. Curr Opin Lipidol 11 101-103 (2000)
  77. The known unknowns of apolipoprotein glycosylation in health and disease. Subramanian SP, Gundry RL. iScience 25 105031 (2022)
  78. A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy. Walsh MT. Am J Pathol 154 11-14 (1999)

Articles citing this publication (278)

  1. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Proc Natl Acad Sci U S A 90 8098-8102 (1993)
  2. MultiCoil: a program for predicting two- and three-stranded coiled coils. Wolf E, Kim PS, Berger B. Protein Sci 6 1179-1189 (1997)
  3. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. Mahley RW, Weisgraber KH, Huang Y. J Lipid Res 50 Suppl S183-8 (2009)
  4. Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module. Fass D, Blacklow S, Kim PS, Berger JM. Nature 388 691-693 (1997)
  5. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT. Proc Natl Acad Sci U S A 92 763-767 (1995)
  6. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Ye S, Huang Y, Müllendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW. Proc Natl Acad Sci U S A 102 18700-18705 (2005)
  7. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, Weisgraber KH. J Biol Chem 277 50380-50385 (2002)
  8. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Chen J, Li Q, Wang J. Proc Natl Acad Sci U S A 108 14813-14818 (2011)
  9. Cholesterol: its regulation and role in central nervous system disorders. Orth M, Bellosta S. Cholesterol 2012 292598 (2012)
  10. Crystal structure of the vinculin tail suggests a pathway for activation. Bakolitsa C, de Pereda JM, Bagshaw CR, Critchley DR, Liddington RC. Cell 99 603-613 (1999)
  11. Structure of a lipid droplet protein; the PAT family member TIP47. Hickenbottom SJ, Kimmel AR, Londos C, Hurley JH. Structure 12 1199-1207 (2004)
  12. Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Fisher C, Beglova N, Blacklow SC. Mol Cell 22 277-283 (2006)
  13. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR. Nat Med 25 496-506 (2019)
  14. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy HM. Proc Natl Acad Sci U S A 103 2126-2131 (2006)
  15. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Zheng G, Chen J, Li H, Glickson JD. Proc Natl Acad Sci U S A 102 17757-17762 (2005)
  16. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. J Virol 86 7256-7267 (2012)
  17. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Lu J, Yu Y, Zhu I, Cheng Y, Sun PD. Proc Natl Acad Sci U S A 111 5189-5194 (2014)
  18. The structural basis of localization and signaling by the focal adhesion targeting domain. Arold ST, Hoellerer MK, Noble ME. Structure 10 319-327 (2002)
  19. Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Babin PJ, Thisse C, Durliat M, Andre M, Akimenko MA, Thisse B. Proc Natl Acad Sci U S A 94 8622-8627 (1997)
  20. Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Gursky O, Atkinson D. Proc Natl Acad Sci U S A 93 2991-2995 (1996)
  21. Apolipoprotein E and cholesterol in aging and disease in the brain. de Chaves EP, Narayanaswami V. Future Lipidol 3 505-530 (2008)
  22. Inter-molecular coiled-coil formation in human apolipoprotein E C-terminal domain. Choy N, Raussens V, Narayanaswami V. J Mol Biol 334 527-539 (2003)
  23. The structural basis of lipid interactions in lipovitellin, a soluble lipoprotein. Anderson TA, Levitt DG, Banaszak LJ. Structure 6 895-909 (1998)
  24. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Nolte RT, Atkinson D. Biophys J 63 1221-1239 (1992)
  25. Expression of maize Adh1 intron mutants in tobacco nuclei. Lou H, McCullough AJ, Schuler MA. Plant J 3 393-403 (1993)
  26. The role of apolipoprotein AI domains in lipid binding. Davidson WS, Hazlett T, Mantulin WW, Jonas A. Proc Natl Acad Sci U S A 93 13605-13610 (1996)
  27. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL, Weisgraber KH. Nat Struct Biol 3 718-722 (1996)
  28. Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. Segall ML, Dhanasekaran P, Baldwin F, Anantharamaiah GM, Weisgraber KH, Phillips MC, Lund-Katz S. J Lipid Res 43 1688-1700 (2002)
  29. Structural basis for the conformational adaptability of apolipophorin III, a helix-bundle exchangeable apolipoprotein. Wang J, Sykes BD, Ryan RO. Proc Natl Acad Sci U S A 99 1188-1193 (2002)
  30. Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms. Hatters DM, Budamagunta MS, Voss JC, Weisgraber KH. J Biol Chem 280 34288-34295 (2005)
  31. Predicting the structure of apolipoprotein A-I in reconstituted high-density lipoprotein disks. Phillips JC, Wriggers W, Li Z, Jonas A, Schulten K. Biophys J 73 2337-2346 (1997)
  32. Structure of human rhinovirus serotype 2 (HRV2). Verdaguer N, Blaas D, Fita I. J Mol Biol 300 1179-1194 (2000)
  33. Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine. Peters-Libeu CA, Newhouse Y, Hatters DM, Weisgraber KH. J Biol Chem 281 1073-1079 (2006)
  34. Effects of polymorphism on the lipid interaction of human apolipoprotein E. Saito H, Dhanasekaran P, Baldwin F, Weisgraber KH, Phillips MC, Lund-Katz S. J Biol Chem 278 40723-40729 (2003)
  35. apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE. Segrest JP, Jones MK, Mishra VK, Anantharamaiah GM, Garber DW. Arterioscler Thromb 14 1674-1685 (1994)
  36. Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. Morrow JA, Arnold KS, Weisgraber KH. Protein Expr Purif 16 224-230 (1999)
  37. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Frieden C, Garai K. Proc Natl Acad Sci U S A 109 8913-8918 (2012)
  38. Apolipoprotein A-I conformation in reconstituted discoidal lipoproteins varying in phospholipid and cholesterol content. Bergeron J, Frank PG, Scales D, Meng QH, Castro G, Marcel YL. J Biol Chem 270 27429-27438 (1995)
  39. Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases. Hashimoto Y, Jiang H, Niikura T, Ito Y, Hagiwara A, Umezawa K, Abe Y, Murayama Y, Nishimoto I. J Neurosci 20 8401-8409 (2000)
  40. Letter Protein folding and calcium binding defects arising from familial hypercholesterolemia mutations of the LDL receptor. Blacklow SC, Kim PS. Nat Struct Biol 3 758-762 (1996)
  41. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. Futamura M, Dhanasekaran P, Handa T, Phillips MC, Lund-Katz S, Saito H. J Biol Chem 280 5414-5422 (2005)
  42. Structural insight into the mechanisms of targeting and signaling of focal adhesion kinase. Liu G, Guibao CD, Zheng J. Mol Cell Biol 22 2751-2760 (2002)
  43. An ER protein functionally couples neutral lipid metabolism on lipid droplets to membrane lipid synthesis in the ER. Markgraf DF, Klemm RW, Junker M, Hannibal-Bach HK, Ejsing CS, Rapoport TA. Cell Rep 6 44-55 (2014)
  44. Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. Pillot T, Goethals M, Najib J, Labeur C, Lins L, Chambaz J, Brasseur R, Vandekerckhove J, Rosseneu M. J Neurochem 72 230-237 (1999)
  45. Characterization of the heparin binding sites in human apolipoprotein E. Saito H, Dhanasekaran P, Nguyen D, Baldwin F, Weisgraber KH, Wehrli S, Phillips MC, Lund-Katz S. J Biol Chem 278 14782-14787 (2003)
  46. Comparison of the stabilities and unfolding pathways of human apolipoprotein E isoforms by differential scanning calorimetry and circular dichroism. Acharya P, Segall ML, Zaiou M, Morrow J, Weisgraber KH, Phillips MC, Lund-Katz S, Snow J. Biochim Biophys Acta 1584 9-19 (2002)
  47. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Wilson C, Mau T, Weisgraber KH, Wardell MR, Mahley RW, Agard DA. Structure 2 713-718 (1994)
  48. Apolipoprotein E4 impairs macrophage efferocytosis and potentiates apoptosis by accelerating endoplasmic reticulum stress. Cash JG, Kuhel DG, Basford JE, Jaeschke A, Chatterjee TK, Weintraub NL, Hui DY. J Biol Chem 287 27876-27884 (2012)
  49. Are membrane proteins "inside-out" proteins? Stevens TJ, Arkin IT. Proteins 36 135-143 (1999)
  50. Analysis of the subgroup A avian sarcoma and leukosis virus receptor: the 40-residue, cysteine-rich, low-density lipoprotein receptor repeat motif of Tva is sufficient to mediate viral entry. Rong L, Bates P. J Virol 69 4847-4853 (1995)
  51. Prevention of phospholipase-C induced aggregation of low density lipoprotein by amphipathic apolipoproteins. Liu H, Scraba DG, Ryan RO. FEBS Lett 316 27-33 (1993)
  52. Hydrogen/deuterium exchange and electron-transfer dissociation mass spectrometry determine the interface and dynamics of apolipoprotein E oligomerization. Huang RY, Garai K, Frieden C, Gross ML. Biochemistry 50 9273-9282 (2011)
  53. A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions. Frieden C, Wang H, Ho CMW. Proc Natl Acad Sci U S A 114 6292-6297 (2017)
  54. Characterization of protein adsorption onto FePt nanoparticles using dual-focus fluorescence correlation spectroscopy. Maffre P, Nienhaus K, Amin F, Parak WJ, Nienhaus GU. Beilstein J Nanotechnol 2 374-383 (2011)
  55. Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. Gutman CR, Strittmatter WJ, Weisgraber KH, Matthew WD. J Neurosci 17 6114-6121 (1997)
  56. The extent of pyrene excimer fluorescence emission is a reflector of distance and flexibility: analysis of the segment linking the LDL receptor-binding and tetramerization domains of apolipoprotein E3. Bains GK, Kim SH, Sorin EJ, Narayanaswami V. Biochemistry 51 6207-6219 (2012)
  57. Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation. Lanfranco MF, Sepulveda J, Kopetsky G, Rebeck GW. Glia 69 1478-1493 (2021)
  58. Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. Minagawa H, Gong JS, Jung CG, Watanabe A, Lund-Katz S, Phillips MC, Saito H, Michikawa M. J Neurosci Res 87 2498-2508 (2009)
  59. Mass spectrometry-based protein footprinting characterizes the structures of oligomeric apolipoprotein E2, E3, and E4. Gau B, Garai K, Frieden C, Gross ML. Biochemistry 50 8117-8126 (2011)
  60. The Alzheimer's disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. Jendresen C, Årskog V, Daws MR, Nilsson LN. J Neuroinflammation 14 59 (2017)
  61. Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices. Sorci-Thomas MG, Bhat S, Thomas MJ. Clin Lipidol 4 113-124 (2009)
  62. Low concentrations of diacylglycerol promote the binding of apolipophorin III to a phospholipid bilayer: a surface plasmon resonance spectroscopy study. Soulages JL, Salamon Z, Wells MA, Tollin G. Proc Natl Acad Sci U S A 92 5650-5654 (1995)
  63. Structure of the minimal interface between ApoE and LRP. Guttman M, Prieto JH, Handel TM, Domaille PJ, Komives EA. J Mol Biol 398 306-319 (2010)
  64. The APO(*)E3-Leiden mouse as an animal model for basal laminar deposit. Kliffen M, Lutgens E, Daemen MJ, de Muinck ED, Mooy CM, de Jong PT. Br J Ophthalmol 84 1415-1419 (2000)
  65. Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice. Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ. Acta Neuropathol Commun 2 75 (2014)
  66. An optimized negative-staining protocol of electron microscopy for apoE4 POPC lipoprotein. Zhang L, Song J, Newhouse Y, Zhang S, Weisgraber KH, Ren G. J Lipid Res 51 1228-1236 (2010)
  67. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Datta G, White CR, Dashti N, Chaddha M, Palgunachari MN, Gupta H, Handattu SP, Garber DW, Anantharamaiah GM. Atherosclerosis 208 134-141 (2010)
  68. Apolipoprotein E*dipalmitoylphosphatidylcholine particles are ellipsoidal in solution. Peters-Libeu CA, Newhouse Y, Hall SC, Witkowska HE, Weisgraber KH. J Lipid Res 48 1035-1044 (2007)
  69. Modulation of the lipid binding properties of the N-terminal domain of human apolipoprotein E3. Weers PM, Narayanaswami V, Ryan RO. Eur J Biochem 268 3728-3735 (2001)
  70. Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake. Kanekiyo T, Bu G. J Biol Chem 284 33352-33359 (2009)
  71. Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution. Chou CY, Lin YL, Huang YC, Sheu SY, Lin TH, Tsay HJ, Chang GG, Shiao MS. Biophys J 88 455-466 (2005)
  72. Contributions of the carboxyl-terminal helical segment to the self-association and lipoprotein preferences of human apolipoprotein E3 and E4 isoforms. Sakamoto T, Tanaka M, Vedhachalam C, Nickel M, Nguyen D, Dhanasekaran P, Phillips MC, Lund-Katz S, Saito H. Biochemistry 47 2968-2977 (2008)
  73. The association−dissociation behavior of the ApoE proteins: kinetic and equilibrium studies. Garai K, Frieden C. Biochemistry 49 9533-9541 (2010)
  74. All-trans-retinoic acid nanodisks. Redmond KA, Nguyen TS, Ryan RO. Int J Pharm 339 246-250 (2007)
  75. Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. Mistry MJ, Clay MA, Kelly ME, Steiner MA, Harmony JA. Cell Immunol 160 14-23 (1995)
  76. Prediction of protein folding class from amino acid composition. Dubchak I, Holbrook SR, Kim SH. Proteins 16 79-91 (1993)
  77. Quantifying size distributions of nanolipoprotein particles with single-particle analysis and molecular dynamic simulations. Blanchette CD, Law R, Benner WH, Pesavento JB, Cappuccio JA, Walsworth V, Kuhn EA, Corzett M, Chromy BA, Segelke BW, Coleman MA, Bench G, Hoeprich PD, Sulchek TA. J Lipid Res 49 1420-1430 (2008)
  78. Receptor mediated yolk protein uptake in the crab Scylla serrata: crustacean vitellogenin receptor recognizes related mammalian serum lipoproteins. Warrier S, Subramoniam T. Mol Reprod Dev 61 536-548 (2002)
  79. A method to recognize distant repeats in protein sequences. Heringa J, Argos P. Proteins 17 391-341 (1993)
  80. Dissociation of apolipoprotein E oligomers to monomer is required for high-affinity binding to phospholipid vesicles. Garai K, Baban B, Frieden C. Biochemistry 50 2550-2558 (2011)
  81. Apolipoprotein E isoform-specific binding to the low-density lipoprotein receptor. Yamamoto T, Choi HW, Ryan RO. Anal Biochem 372 222-226 (2008)
  82. A unified scheme for initiation and conformational adaptation of human apolipoprotein E N-terminal domain upon lipoprotein binding and for receptor binding activity. Sivashanmugam A, Wang J. J Biol Chem 284 14657-14666 (2009)
  83. Identification of key residues in subgroup A avian leukosis virus envelope determining receptor binding affinity and infectivity of cells expressing chicken or quail Tva receptor. Holmen SL, Melder DC, Federspiel MJ. J Virol 75 726-737 (2001)
  84. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. Olsson U, Camejo G, Hurt-Camejo E, Elfsber K, Wiklund O, Bondjers G. Arterioscler Thromb Vasc Biol 17 149-155 (1997)
  85. Structural and sequence characteristics of long alpha helices in globular proteins. Kumar S, Bansal M. Biophys J 71 1574-1586 (1996)
  86. Do G protein subunits associate via a three-stranded coiled coil? Lupas AN, Lupas JM, Stock JB. FEBS Lett 314 105-108 (1992)
  87. Role of basic residues in the subgroup-determining region of the subgroup A avian sarcoma and leukosis virus envelope in receptor binding and infection. Rong L, Edinger A, Bates P. J Virol 71 3458-3465 (1997)
  88. Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Dietrich M, Hu Y, Block G, Olano E, Packer L, Morrow JD, Hudes M, Abdukeyum G, Rimbach G, Minihane AM. Lipids 40 329-334 (2005)
  89. Decoding of lipoprotein-receptor interactions: properties of ligand binding modules governing interactions with apolipoprotein E. Guttman M, Prieto JH, Croy JE, Komives EA. Biochemistry 49 1207-1216 (2010)
  90. High- and low-temperature unfolding of human high-density apolipoprotein A-2. Gursky O, Atkinson D. Protein Sci 5 1874-1882 (1996)
  91. Structural and functional variations in human apolipoprotein E3 and E4. Chou CY, Jen WP, Hsieh YH, Shiao MS, Chang GG. J Biol Chem 281 13333-13344 (2006)
  92. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42. Dafnis I, Stratikos E, Tzinia A, Tsilibary EC, Zannis VI, Chroni A. J Neurochem 115 873-884 (2010)
  93. Apolipoprotein E in the brain and its role in Alzheimer's disease. Poirier J. J Psychiatry Neurosci 21 128-134 (1996)
  94. Isolation and characterization of an antifreeze protein from the longhorn sculpin, Myoxocephalus octodecimspinosis. Deng G, Laursen RA. Biochim Biophys Acta 1388 305-314 (1998)
  95. Lipopolysaccharide binding of an exchangeable apolipoprotein, apolipophorin III, from Galleria mellonella. Pratt CC, Weers PM. Biol Chem 385 1113-1119 (2004)
  96. Apo E variants in patients with type III hyperlipoproteinemia. Civeira F, Pocoví M, Cenarro A, Casao E, Vilella E, Joven J, González J, Garcia-Otín AL, Ordovás JM. Atherosclerosis 127 273-282 (1996)
  97. Conformational flexibility in the apolipoprotein E amino-terminal domain structure determined from three new crystal forms: implications for lipid binding. Segelke BW, Forstner M, Knapp M, Trakhanov SD, Parkin S, Newhouse YM, Bellamy HD, Weisgraber KH, Rupp B. Protein Sci 9 886-897 (2000)
  98. Engineering conformational destabilization into mouse apolipoprotein E. A model for a unique property of human apolipoprotein E4. Hatters DM, Peters-Libeu CA, Weisgraber KH. J Biol Chem 280 26477-26482 (2005)
  99. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Amarzguioui M, Mucchiano G, Häggqvist B, Westermark P, Kavlie A, Sletten K, Prydz H. Biochem Biophys Res Commun 242 534-539 (1998)
  100. Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Yamauchi Y, Deguchi N, Takagi C, Tanaka M, Dhanasekaran P, Nakano M, Handa T, Phillips MC, Lund-Katz S, Saito H. Biochemistry 47 6702-6710 (2008)
  101. A three-dimensional homology model of lipid-free apolipoprotein A-IV using cross-linking and mass spectrometry. Tubb MR, Silva RA, Fang J, Tso P, Davidson WS. J Biol Chem 283 17314-17323 (2008)
  102. Apolipophorin III: a lipid-triggered molecular switch. Weers PM, Ryan RO. Insect Biochem Mol Biol 33 1249-1260 (2003)
  103. Function and comorbidities of apolipoprotein e in Alzheimer's disease. Leduc V, Domenger D, De Beaumont L, Lalonde D, Bélanger-Jasmin S, Poirier J. Int J Alzheimers Dis 2011 974361 (2011)
  104. N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Sheng Z, Prorok M, Brown BE, Castellino FJ. Neuropharmacology 55 204-214 (2008)
  105. A molecular trigger of lipid binding-induced opening of a helix bundle exchangeable apolipoprotein. Narayanaswami V, Wang J, Schieve D, Kay CM, Ryan RO. Proc Natl Acad Sci U S A 96 4366-4371 (1999)
  106. A new cryptic cationic antimicrobial peptide from human apolipoprotein E with antibacterial activity and immunomodulatory effects on human cells. Pane K, Sgambati V, Zanfardino A, Smaldone G, Cafaro V, Angrisano T, Pedone E, Di Gaetano S, Capasso D, Haney EF, Izzo V, Varcamonti M, Notomista E, Hancock RE, Di Donato A, Pizzo E. FEBS J 283 2115-2131 (2016)
  107. Differences in the binding capacity of human apolipoprotein E3 and E4 to size-fractionated lipid emulsions. Perugini MA, Schuck P, Howlett GJ. Eur J Biochem 269 5939-5949 (2002)
  108. Identification of a heparin-binding region of rat thyroglobulin involved in megalin binding. Marinò M, Friedlander JA, McCluskey RT, Andrews D. J Biol Chem 274 30377-30386 (1999)
  109. Orientation and mode of lipid-binding interaction of human apolipoprotein E C-terminal domain. Raussens V, Drury J, Forte TM, Choy N, Goormaghtigh E, Ruysschaert JM, Narayanaswami V. Biochem J 387 747-754 (2005)
  110. Sequence and structure of human rhinoviruses reveal the basis of receptor discrimination. Vlasak M, Blomqvist S, Hovi T, Hewat E, Blaas D. J Virol 77 6923-6930 (2003)
  111. Concerning the structure of apoE. Frieden C, Garai K. Protein Sci 22 1820-1825 (2013)
  112. Crystallization, structure determination and least-squares refinement to 1.75 A resolution of the fatty-acid-binding protein isolated from Manduca sexta L. Benning MM, Smith AF, Wells MA, Holden HM. J Mol Biol 228 208-219 (1992)
  113. Helical structure, stability, and dynamics in human apolipoprotein E3 and E4 by hydrogen exchange and mass spectrometry. Chetty PS, Mayne L, Lund-Katz S, Englander SW, Phillips MC. Proc Natl Acad Sci U S A 114 968-973 (2017)
  114. The structure of dimeric apolipoprotein A-IV and its mechanism of self-association. Deng X, Morris J, Dressmen J, Tubb MR, Tso P, Jerome WG, Davidson WS, Thompson TB. Structure 20 767-779 (2012)
  115. Apolipophorin III: lipopolysaccharide binding requires helix bundle opening. Leon LJ, Idangodage H, Wan CP, Weers PM. Biochem Biophys Res Commun 348 1328-1333 (2006)
  116. Lipid binding ability of human apolipoprotein E N-terminal domain isoforms: correlation with protein stability? Weers PM, Narayanaswami V, Choy N, Luty R, Hicks L, Kay CM, Ryan RO. Biophys Chem 100 481-492 (2003)
  117. Sortilin facilitates signaling of ciliary neurotrophic factor and related helical type 1 cytokines targeting the gp130/leukemia inhibitory factor receptor beta heterodimer. Larsen JV, Hansen M, Møller B, Madsen P, Scheller J, Nielsen M, Petersen CM. Mol Cell Biol 30 4175-4187 (2010)
  118. The C terminus of apolipoprotein A-V modulates lipid-binding activity. Beckstead JA, Wong K, Gupta V, Wan CP, Cook VR, Weinberg RB, Weers PM, Ryan RO. J Biol Chem 282 15484-15489 (2007)
  119. Homology model of juvenile hormone esterase from the crop pest, Heliothis virescens. Thomas BA, Church WB, Lane TR, Hammock BD. Proteins 34 184-196 (1999)
  120. Modification by acrolein, a component of tobacco smoke and age-related oxidative stress, mediates functional impairment of human apolipoprotein E. Tamamizu-Kato S, Wong JY, Jairam V, Uchida K, Raussens V, Kato H, Ruysschaert JM, Narayanaswami V. Biochemistry 46 8392-8400 (2007)
  121. NMR structure of a concatemer of the first and second ligand-binding modules of the human low-density lipoprotein receptor. Kurniawan ND, Atkins AR, Bieri S, Brown CJ, Brereton IM, Kroon PA, Smith R. Protein Sci 9 1282-1293 (2000)
  122. Recombinant locust apolipophorin III: characterization and NMR spectroscopy. Weers PM, Wang J, Van der Horst DJ, Kay CM, Sykes BD, Ryan RO. Biochim Biophys Acta 1393 99-107 (1998)
  123. An M(r) 145,000 low-density lipoprotein (LDL)-binding protein is conserved throughout the Kinetoplastida order. Bastin P, Stephan A, Raper J, Saint-Remy JM, Opperdoes FR, Courtoy PJ. Mol Biochem Parasitol 76 43-56 (1996)
  124. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Chroni A, Pyrpassopoulos S, Thanassoulas A, Nounesis G, Zannis VI, Stratikos E. Biochemistry 47 9071-9080 (2008)
  125. The "beta-clasp" model of apolipoprotein A-I--a lipid-free solution structure determined by electron paramagnetic resonance spectroscopy. Lagerstedt JO, Budamagunta MS, Liu GS, DeValle NC, Voss JC, Oda MN. Biochim Biophys Acta 1821 448-455 (2012)
  126. The structure of human apolipoprotein E2, E3 and E4 in solution. 2. Multidomain organization correlates with the stability of apoE structure. Clément-Collin V, Barbier A, Dergunov AD, Visvikis A, Siest G, Desmadril M, Takahashi M, Aggerbeck LP. Biophys Chem 119 170-185 (2006)
  127. Very low density lipoprotein receptor binds apolipoprotein E2/2 as well as apolipoprotein E3/3. Takahashi S, Oida K, Ookubo M, Suzuki J, Kohno M, Murase T, Yamamoto T, Nakai T. FEBS Lett 386 197-200 (1996)
  128. A novel coiled-coil repeat variant in a class of bacterial cytoskeletal proteins. Walshaw J, Gillespie MD, Kelemen GH. J Struct Biol 170 202-215 (2010)
  129. An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines. Dafnis I, Tzinia AK, Tsilibary EC, Zannis VI, Chroni A. Neuroscience 210 21-32 (2012)
  130. Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28-->Pro), on lipoproteins and the prevalence of coronary artery disease in whites. Orth M, Weng W, Funke H, Steinmetz A, Assmann G, Nauck M, Dierkes J, Ambrosch A, Weisgraber KH, Mahley RW, Wieland H, Luley C. Arterioscler Thromb Vasc Biol 19 1306-1315 (1999)
  131. Primary structure of apolipophorin-III from the greater wax moth, Galleria mellonella. Weise C, Franke P, Kopácek P, Wiesner A. J Protein Chem 17 633-641 (1998)
  132. S-nitrosylation of ApoE in Alzheimer's disease. Abrams AJ, Farooq A, Wang G. Biochemistry 50 3405-3407 (2011)
  133. Truncated apo B-70.5-containing lipoproteins bind to megalin but not the LDL receptor. Chen Z, Saffitz JE, Latour MA, Schonfeld G. J Clin Invest 103 1419-1430 (1999)
  134. Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. van den Maagdenberg AM, Weng W, de Bruijn IH, de Knijff P, Funke H, Smelt AH, Gevers Leuven JA, van't Hooft FM, Assmann G, Hofker MH. Am J Hum Genet 52 937-946 (1993)
  135. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. Elder GA, Cho JY, English DF, Franciosi S, Schmeidler J, Sosa MA, Gasperi RD, Fisher EA, Mathews PM, Haroutunian V, Buxbaum JD. J Neurochem 102 1220-1231 (2007)
  136. LDL receptor/lipoprotein recognition: endosomal weakening of ApoB and ApoE binding to the convex face of the LR5 repeat. Martínez-Oliván J, Arias-Moreno X, Velazquez-Campoy A, Millet O, Sancho J. FEBS J 281 1534-1546 (2014)
  137. Sense and antisense transcripts of the apolipoprotein E gene in normal and ApoE knockout mice, their expression after spinal cord injury and corresponding human transcripts. Seitz A, Gourevitch D, Zhang XM, Clark L, Chen P, Kragol M, Levenkova N, Rux J, Samulewicz S, Heber-Katz E. Hum Mol Genet 14 2661-2670 (2005)
  138. Impact of self-association on function of apolipoprotein A-I. Jayaraman S, Abe-Dohmae S, Yokoyama S, Cavigiolio G. J Biol Chem 286 35610-35623 (2011)
  139. Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy. Hatters DM, Voss JC, Budamagunta MS, Newhouse YN, Weisgraber KH. J Mol Biol 386 261-271 (2009)
  140. Lipidated apolipoprotein E4 structure and its receptor binding mechanism determined by a combined cross-linking coupled to mass spectrometry and molecular dynamics approach. Henry N, Krammer EM, Stengel F, Adams Q, Van Liefferinge F, Hubin E, Chaves R, Efremov R, Aebersold R, Vandenbussche G, Prévost M, Raussens V, Deroo S. PLoS Comput Biol 14 e1006165 (2018)
  141. Quantitative dissection of the binding contributions of ligand lysines of the receptor-associated protein (RAP) to the low density lipoprotein receptor-related protein (LRP1). Dolmer K, Campos A, Gettins PG. J Biol Chem 288 24081-24090 (2013)
  142. Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia. Mendoza-Barberá E, Julve J, Nilsson SK, Lookene A, Martín-Campos JM, Roig R, Lechuga-Sancho AM, Sloan JH, Fuentes-Prior P, Blanco-Vaca F. J Lipid Res 54 649-661 (2013)
  143. The conformation of lipid-free human apolipoprotein A-I in solution. Pollard RD, Fulp B, Samuel MP, Sorci-Thomas MG, Thomas MJ. Biochemistry 52 9470-9481 (2013)
  144. Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Khumsupan P, Ramirez R, Khumsupan D, Narayanaswami V. Biochim Biophys Acta 1808 352-359 (2011)
  145. Influence of N-terminal helix bundle stability on the lipid-binding properties of human apolipoprotein A-I. Tanaka M, Dhanasekaran P, Nguyen D, Nickel M, Takechi Y, Lund-Katz S, Phillips MC, Saito H. Biochim Biophys Acta 1811 25-30 (2011)
  146. Purification of juvenile hormone esterase and molecular cloning of the cDNA from Manduca sexta. Hinton AC, Hammock BD. Insect Biochem Mol Biol 32 57-66 (2001)
  147. Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices. Lins L, Thomas-Soumarmon A, Pillot T, Vandekerchkhove J, Rosseneu M, Brasseur R. J Neurochem 73 758-769 (1999)
  148. Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry. Tran TN, Kosaraju MG, Tamamizu-Kato S, Akintunde O, Zheng Y, Bielicki JK, Pinkerton K, Uchida K, Lee YY, Narayanaswami V. Biochemistry 53 361-375 (2014)
  149. Carboxyl-terminal domain of human apolipoprotein E: expression, purification, and crystallization. Forstner M, Peters-Libeu C, Contreras-Forrest E, Newhouse Y, Knapp M, Rupp B, Weisgraber KH. Protein Expr Purif 17 267-272 (1999)
  150. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). Mann WA, Lohse P, Gregg RE, Ronan R, Hoeg JM, Zech LA, Brewer HB. J Clin Invest 96 1100-1107 (1995)
  151. Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Pillot T, Goethals M, Vanloo B, Lins L, Brasseur R, Vandekerckhove J, Rosseneu M. Eur J Biochem 243 650-659 (1997)
  152. An efficient on-column expressed protein ligation strategy: application to segmental triple labeling of human apolipoprotein E3. Zhao W, Zhang Y, Cui C, Li Q, Wang J. Protein Sci 17 736-747 (2008)
  153. Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia. Hoffer MJ, Niththyananthan S, Naoumova RP, Kibirige MS, Frants RR, Havekes LM, Thompson GR. Atherosclerosis 124 183-189 (1996)
  154. Expressed protein ligation using an N-terminal cysteine containing fragment generated in vivo from a pelB fusion protein. Hauser PS, Ryan RO. Protein Expr Purif 54 227-233 (2007)
  155. Localization of basic residues required for receptor binding to the single alpha-helix of the receptor binding domain of human alpha2-macroglobulin. Huang W, Dolmer K, Liao X, Gettins PG. Protein Sci 7 2602-2612 (1998)
  156. Molecular dynamics on a model for nascent high-density lipoprotein: role of salt bridges. Sheldahl C, Harvey SC. Biophys J 76 1190-1198 (1999)
  157. Native Mass Spectrometry, Ion Mobility, Electron-Capture Dissociation, and Modeling Provide Structural Information for Gas-Phase Apolipoprotein E Oligomers. Wang H, Eschweiler J, Cui W, Zhang H, Frieden C, Ruotolo BT, Gross ML. J Am Soc Mass Spectrom 30 876-885 (2019)
  158. Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells. Ali K, Lund-Katz S, Lawson J, Phillips MC, Rader DJ. Atherosclerosis 196 201-209 (2008)
  159. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. de Villiers WJ, van der Westhuyzen DR, Coetzee GA, Henderson HE, Marais AD. Arterioscler Thromb Vasc Biol 17 865-872 (1997)
  160. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. Mitani A, Ishigami M, Watase K, Minakata T, Yamamura T. J Atheroscler Thromb 18 531-535 (2011)
  161. Apolipoprotein E-low density lipoprotein receptor binding: study of protein-protein interaction in rationally selected docked complexes. Prévost M, Raussens V. Proteins 55 874-884 (2004)
  162. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Civeira F, Cenarro A, Ferrando J, Puzo J, Garcia-Otín AL, Mozas P, Pocoví M. Am Heart J 138 156-162 (1999)
  163. Fluorescence analysis of the lipid binding-induced conformational change of apolipoprotein E4. Mizuguchi C, Hata M, Dhanasekaran P, Nickel M, Phillips MC, Lund-Katz S, Saito H. Biochemistry 51 5580-5588 (2012)
  164. Fluorescence resonance energy transfer analysis of apolipoprotein E C-terminal domain and amyloid beta peptide (1-42) interaction. Phu MJ, Hawbecker SK, Narayanaswami V. J Neurosci Res 80 877-886 (2005)
  165. Helix-helix interactions in reconstituted high-density lipoproteins. Lins L, Brasseur R, De Pauw M, Van Biervliet JP, Ruysschaert JM, Rosseneu M, Vanloo B. Biochim Biophys Acta 1258 10-18 (1995)
  166. Isolation, characterization, and stability of discretely-sized nanolipoprotein particles assembled with apolipophorin-III. Fischer NO, Blanchette CD, Segelke BW, Corzett M, Chromy BA, Kuhn EA, Bench G, Hoeprich PD. PLoS One 5 e11643 (2010)
  167. Structural differences between apolipoprotein E3 and E4 as measured by (19)F NMR. Garai K, Mustafi SM, Baban B, Frieden C. Protein Sci 19 66-74 (2010)
  168. Structure of a rat α₁-macroglobulin receptor-binding domain dimer. Xiao T, DeCamp DL, Sprang SR. Protein Sci 9 1889-1897 (2000)
  169. ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations. Williams B, Convertino M, Das J, Dokholyan NV. PLoS Comput Biol 11 e1004359 (2015)
  170. ApoE: the role of conserved residues in defining function. Frieden C. Protein Sci 24 138-144 (2015)
  171. Association of APOE-C1 gene cluster polymorphisms with gallstone disease. Dixit M, Choudhuri G, Mittal B. Dig Liver Dis 38 397-403 (2006)
  172. Biochemical and biophysical characterization of recombinant rat apolipoprotein E: similarities to human apolipoprotein E3. Tran TN, Kim SH, Gallo C, Amaya M, Kyees J, Narayanaswami V. Arch Biochem Biophys 529 18-25 (2013)
  173. Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Dergunov AD, Smirnova EA, Merched A, Visvikis S, Siest G, Yakushkin VV, Tsibulsky V. Biochim Biophys Acta 1484 14-28 (2000)
  174. Human apolipoprotein E as a reservoir of cryptic bioactive peptides: The case of ApoE 133-167. Zanfardino A, Bosso A, Gallo G, Pistorio V, Di Napoli M, Gaglione R, Dell'Olmo E, Varcamonti M, Notomista E, Arciello A, Pizzo E. J Pept Sci 24 e3095 (2018)
  175. Linker chains of the gigantic hemoglobin of the earthworm Lumbricus terrestris: primary structures of linkers L2, L3, and L4 and analysis of the connectivity of the disulfide bonds in linker L1. Kao WY, Qin J, Fushitani K, Smith SS, Gorr TA, Riggs CK, Knapp JE, Chait BT, Riggs AF. Proteins 63 174-187 (2006)
  176. Mimicking lipid-binding-induced conformational changes in the human apolipoprotein E N-terminal receptor binding domain effects of low pH and propanol. Clément-Collin V, Leroy A, Monteilhet C, Aggerbeck LP. Eur J Biochem 264 358-368 (1999)
  177. Molecular basis for increased risk for late-onset Alzheimer disease due to the naturally occurring L28P mutation in apolipoprotein E4. Argyri L, Dafnis I, Theodossiou TA, Gantz D, Stratikos E, Chroni A. J Biol Chem 289 12931-12945 (2014)
  178. Molecular cloning and expression characterization of ApoC-I in the orange-spotted grouper. Wang Y, Zhou L, Li Z, Gui JF. Fish Physiol Biochem 34 339-348 (2008)
  179. Probing the conformation of a human apolipoprotein C-1 by amino acid substitutions and trimethylamine-N-oxide. Gursky O. Protein Sci 8 2055-2064 (1999)
  180. The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis. Rudenko G, Bonten E, Hol WG, d'Azzo A. Proc Natl Acad Sci U S A 95 621-625 (1998)
  181. Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia. Gorshkova IN, Kypreos KE, Gantz DL, Zannis VI, Atkinson D. Biochemistry 47 12644-12654 (2008)
  182. Characterization of low density lipoprotein receptor ligand interactions by fluorescence resonance energy transfer. Yamamoto T, Lamoureux J, Ryan RO. J Lipid Res 47 1091-1096 (2006)
  183. Extracellular Interactions between Hepatitis C Virus and Secreted Apolipoprotein E. Li Z, Li Y, Bi Y, Zhang H, Yao Y, Li Q, Cun W, Dong S. J Virol 91 e02227-16 (2017)
  184. Low affinity binding of plasma proteins to lipid-coated quantum dots as observed by in situ fluorescence correlation spectroscopy. Klapper Y, Maffre P, Shang L, Ekdahl KN, Nilsson B, Hettler S, Dries M, Gerthsen D, Nienhaus GU. Nanoscale 7 9980-9984 (2015)
  185. Role of an intramolecular contact on lipoprotein uptake by the LDL receptor. Zhao Z, Michaely P. Biochim Biophys Acta 1811 397-408 (2011)
  186. The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture. Wong K, Beckstead JA, Lee D, Weers PM, Guigard E, Kay CM, Ryan RO. Biochemistry 47 8768-8774 (2008)
  187. The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers. Wang X, Han J, Hardie DB, Yang J, Borchers CH. J Mass Spectrom 51 86-95 (2016)
  188. A thyroid hormone binding motif is evolutionarily conserved in apolipoproteins. Benvenga S. Thyroid 7 605-611 (1997)
  189. Analysis of differentially expressed novel post-translational modifications of plasma apolipoprotein E in Taiwanese females with breast cancer. Uen YH, Liao CC, Lin JC, Pan YH, Liu YC, Chen YC, Chen WJ, Tai CC, Lee KW, Liu YR, Lin HT, Lin CY. J Proteomics 126 252-262 (2015)
  190. Atomistic Insights into Structural Differences between E3 and E4 Isoforms of Apolipoprotein E. Ray A, Ahalawat N, Mondal J. Biophys J 113 2682-2694 (2017)
  191. C-terminal interactions of apolipoprotein E4 respond to the postprandial state. Tetali SD, Budamagunta MS, Voss JC, Rutledge JC. J Lipid Res 47 1358-1365 (2006)
  192. Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces. Meyers NL, Wang L, Gursky O, Small DM. J Lipid Res 54 1927-1938 (2013)
  193. Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81->Lys, Cys112->Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis. Ruzicka V, März W, Russ A, Fisher E, Mondorf W, Gross W. Electrophoresis 14 1032-1037 (1993)
  194. Enzymatic hydrolysis of reconstituted dimyristoylphosphatidylcholine-apo A-I complexes. Lins L, Piron S, Conrath K, Vanloo B, Brasseur R, Rosseneu M, Baert J, Ruysschaert JM. Biochim Biophys Acta 1151 137-142 (1993)
  195. Essential role of the conformational flexibility of helices 1 and 5 on the lipid binding activity of apolipophorin-III. Soulages JL, Arrese EL, Chetty PS, Rodriguez V. J Biol Chem 276 34162-34166 (2001)
  196. Kinetic analysis of binding interaction between the subgroup A Rous sarcoma virus glycoprotein SU and its cognate receptor Tva: calcium is not required for ligand binding. Yu X, Wang QY, Guo Y, Dolmer K, Young JA, Gettins PG, Rong L. J Virol 77 7517-7526 (2003)
  197. Lipoprotein assembly and function in an evolutionary perspective. Van der Horst DJ, Rodenburg KW. Biomol Concepts 1 165-183 (2010)
  198. RNA interference mediated knockdown of apolipophorin-III leads to knockdown of manganese superoxide dismutase in Hyphantria cunea. Kim YI, Kim HJ, Kwon YM, Kang YJ, Lee IH, Jin BR, Han YS, Kim I, Cheon HM, Ha NG, Seo SJ. Comp Biochem Physiol A Mol Integr Physiol 159 303-312 (2011)
  199. The serine protease HtrA1 contributes to the formation of an extracellular 25-kDa apolipoprotein E fragment that stimulates neuritogenesis. Muñoz SS, Li H, Ruberu K, Chu Q, Saghatelian A, Ooi L, Garner B. J Biol Chem 293 4071-4084 (2018)
  200. Apolipoprotein ε7 allele in memory complaints: insights through protein structure prediction. Youn YC, Lim YK, Han SH, Giau VV, Lee MK, Park KY, Kim S, Bagyinszky E, An SSA, Kim HR. Clin Interv Aging 12 1095-1102 (2017)
  201. A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice. Xu Y, Liu H, Liu M, Li F, Liu L, Du F, Fan D, Yu H. Am J Transl Res 8 3482-3492 (2016)
  202. Apolipoprotein E Signals via TLR4 to Induce CXCL5 Secretion by Asthmatic Airway Epithelial Cells. Kalchiem-Dekel O, Yao X, Barochia AV, Kaler M, Figueroa DM, Karkowsky WB, Gordon EM, Gao M, Fergusson MM, Qu X, Liu P, Li Y, Seifuddin F, Pirooznia M, Levine SJ. Am J Respir Cell Mol Biol 63 185-197 (2020)
  203. C-terminal apolipoprotein E-derived peptide, Ep1.B, displays anti-atherogenic activity. Bocksch L, Rider BJ, Stephens T, Dai E, Liu L, Diao H, Viswanathan K, Munuswamy-Ramanujam G, Singh B, Lucas A. Atherosclerosis 194 116-124 (2007)
  204. Folding stability of the kinetoplastid membrane protein-11 (KMP-11) from Leishmania infantum. Fuertes MA, Berberich C, Lozano RM, Gimenez-Gallego G, Alonso C. Eur J Biochem 260 559-567 (1999)
  205. Neuronal cell apoptosis by a receptor-binding domain peptide of ApoE4, not through low-density lipoprotein receptor-related protein. Hagiwara A, Hashimoto Y, Niikura T, Ito Y, Terashita K, Kita Y, Nishimoto I, Umezawa K. Biochem Biophys Res Commun 278 633-639 (2000)
  206. Role of secondary structure in protein-phospholipid surface interactions: reconstitution and denaturation of apolipoprotein C-I:DMPC complexes. Benjwal S, Jayaraman S, Gursky O. Biochemistry 46 4184-4194 (2007)
  207. The number of cysteine residues per mole in apolipoprotein E affects systematically synchronous neural interactions in women's healthy brains. Leuthold AC, Mahan MY, Stanwyck JJ, Georgopoulos A, Georgopoulos AP. Exp Brain Res 226 525-536 (2013)
  208. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins. Mulder M, van der Boom H, de Knijff P, Braam C, van den Maagdenberg A, Leuven JA, Havekes LM. Atherosclerosis 108 183-192 (1994)
  209. A complete backbone spectral assignment of lipid-free human apolipoprotein E (apoE). Zhang Y, Chen J, Wang J. Biomol NMR Assign 2 207-210 (2008)
  210. A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Zhao W, Du F, Zhang M, Sun S, Yu H, Fan D. Exp Biol Med (Maywood) 236 1468-1476 (2011)
  211. Apolipophorin III from Hyphantria cunea shows different anti-oxidant ability against LDL oxidation in the lipid-free and lipid-bound state. Seo SJ, Park KH, Cho KH. Comp Biochem Physiol B Biochem Mol Biol 151 433-439 (2008)
  212. Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants. Wong-Mauldin K, Raussens V, Forte TM, Ryan RO. J Biol Chem 284 33369-33376 (2009)
  213. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides. de Beer F, van Dijk KW, Jong MC, van Vark LC, van der Zee A, Hofker MH, Fallaux FJ, Hoeben RC, Smelt AH, Havekes LM. Arterioscler Thromb Vasc Biol 20 1800-1806 (2000)
  214. Displacement of apolipophorin III from the surface of low density lipophorin by human apolipoprotein A-I. Liu H, Malhotra V, Ryan RO. Biochem Biophys Res Commun 179 734-740 (1991)
  215. Exogenous glucocorticoids increase macrophage secretion of apo E by cholesterol-independent pathways. Zuckerman SH, Evans GF, O'Neal L. Atherosclerosis 103 43-54 (1993)
  216. NMR studies of the low-density lipoprotein receptor-binding peptide of apolipoprotein E bound to dodecylphosphocholine micelles. Clayton D, Brereton IM, Kroon PA, Smith R. Protein Sci 8 1797-1805 (1999)
  217. The low-density lipoprotein receptor-related protein associates with calnexin, calreticulin, and protein disulfide isomerase in receptor-associated-protein-deficient fibroblasts. Orlando RA. Exp Cell Res 294 244-253 (2004)
  218. The role of hydrophobic and negatively charged surface patches of lipid-free apolipoprotein A-I in lipid binding and ABCA1-mediated cholesterol efflux. Smith LE, Davidson WS. Biochim Biophys Acta 1801 64-69 (2010)
  219. Apolipoprotein E knockout mice have accentuated malnutrition with mucosal disruption and blunted insulin-like growth factor I responses to refeeding. Oriá RB, Vieira CM, Pinkerton RC, de Castro Costa CM, Lopes MB, Hussaini I, Shi W, Brito GA, Lima AA, Guerrant RL. Nutr Res 26 427-435 (2006)
  220. Apolipoprotein E phylogeny and evolution. Kasap M, Sazci A, Akpinar G, Ergul E. Cell Biochem Funct 26 43-50 (2008)
  221. Fluorescence study of domain structure and lipid interaction of human apolipoproteins E3 and E4. Mizuguchi C, Hata M, Dhanasekaran P, Nickel M, Okuhira K, Phillips MC, Lund-Katz S, Saito H. Biochim Biophys Acta 1841 1716-1724 (2014)
  222. Identification, expression and function of apolipoprotein E in annual fish Nothobranchius guentheri: implication for an aging marker. Wang X, Shang X, Luan J, Zhang S. Biogerontology 15 233-243 (2014)
  223. Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle. Morris JK, McCoin CS, Fuller KN, John CS, Wilkins HM, Green ZD, Wang X, Sharma P, Burns JM, Vidoni ED, Mahnken JD, Shankar K, Swerdlow RH, Thyfault JP. Function (Oxf) 2 zqab045 (2021)
  224. A simple approach for human recombinant apolipoprotein E4 expression and purification. Argyri L, Skamnaki V, Stratikos E, Chroni A. Protein Expr Purif 79 251-257 (2011)
  225. Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study. Corsetti JP, Gansevoort RT, Bakker SJL, Dullaart RPF. J Clin Lipidol 10 842-850 (2016)
  226. Apolipoprotein E4 has extensive conformational heterogeneity in lipid-free and lipid-bound forms. Stuchell-Brereton MD, Zimmerman MI, Miller JJ, Mallimadugula UL, Incicco JJ, Roy D, Smith LG, Cubuk J, Baban B, DeKoster GT, Frieden C, Bowman GR, Soranno A. Proc Natl Acad Sci U S A 120 e2215371120 (2023)
  227. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Vezeridis AM, Chroni A, Zannis VI. Ann Med 43 302-311 (2011)
  228. Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Sijbrands EJ, Westendorp RG, Hoffer MJ, Frants RR, Meinders AE, Souverijn JH, Gevers Leuven JA, Van der Laarse A, Havekes LM, Smelt AH. Atherosclerosis 126 197-205 (1996)
  229. Hidden Aggregation Hot-Spots on Human Apolipoprotein E: A Structural Study. Tsiolaki PL, Katsafana AD, Baltoumas FA, Louros NN, Iconomidou VA. Int J Mol Sci 20 E2274 (2019)
  230. Mechanism of Lipid Binding of Human Apolipoprotein E3 by Hydrogen/Deuterium Exchange/Mass Spectrometry and Fluorescence Polarization. Fabilane CS, Nguyen PN, Hernandez RV, Nirudodhi S, Duong M, Maier CS, Narayanaswami V. Protein Pept Lett 23 404-413 (2016)
  231. Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4. Vezeridis AM, Drosatos K, Zannis VI. J Lipid Res 52 45-56 (2011)
  232. Regulation by estrogen of synthesis and secretion of apolipoprotein A-I in the chicken hepatoma cell line, LMH-2A. Hermann M, Foisner R, Schneider WJ, Ivessa NE. Biochim Biophys Acta 1641 25-33 (2003)
  233. Replacement of helix 1' enhances the lipid binding activity of apoE3 N-terminal domain. Redmond KA, Murphy C, Narayanaswami V, Kiss RS, Hauser P, Guigard E, Kay CM, Ryan RO. FEBS J 273 558-567 (2006)
  234. Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship. Lek MT, Cruz S, Ibe NU, Beck WHJ, Bielicki JK, Weers PMM, Narayanaswami V. PLoS One 12 e0178346 (2017)
  235. A pyrene based fluorescence approach to study conformation of apolipoprotein E3 in macrophage-generated nascent high density lipoprotein. Kim SH, Kothari S, Patel AB, Bielicki JK, Narayanaswami V. Biochem Biophys Res Commun 450 124-128 (2014)
  236. Anatomy by computer experiment of the exchange of a water molecule buried in human apolipoprotein E. Prévost M. Fold Des 3 345-351 (1998)
  237. Apolipoprotein E particle size is increased in Alzheimer's disease. Nelson TJ, Sen A. Alzheimers Dement (Amst) 11 10-18 (2019)
  238. Chemical modification of low-density lipoprotein enhances the number of binding sites for divalent cations. Pifat G, Brnjas-Kraljević J, Jürgens G, Herak-Kramberger CM, Herak JN. Chem Phys Lipids 63 159-167 (1992)
  239. Dietary fat clearance in type V hyperlipoproteinaemia secondary to a rare variant of human apolipoprotein E: the apolipoprotein E3 (Arg 136-->Ser) Vialettes B, Reynier P, Atlan-Gepner C, Mekki N, Lesluyes-Mazzochi L, Luc G, Lairon D, Malthiery Y. Br J Nutr 83 615-622 (2000)
  240. Instability of crab vitellogenin and its immunological relatedness with mammalian atherogenic lipoproteins. Warrier SR, Subramoniam T. Mol Reprod Dev 64 329-340 (2003)
  241. LilrB3 is a putative cell surface receptor of APOE4. Zhou J, Wang Y, Huang G, Yang M, Zhu Y, Jin C, Jing D, Ji K, Shi Y. Cell Res 33 116-130 (2023)
  242. Apolipophorin III lysine modification: Effect on structure and lipid binding. Vasquez LJ, Abdullahi GE, Wan CP, Weers PM. Biochim Biophys Acta 1788 1901-1906 (2009)
  243. Apolipoprotein E3-mediated cellular uptake of reconstituted high-density lipoprotein bearing core 3, 10, or 17 nm hydrophobic gold nanoparticles. Chuang ST, Shon YS, Narayanaswami V. Int J Nanomedicine 12 8495-8510 (2017)
  244. Apolipoprotein E3Basel: new insights into a highly conserved protein region. Miserez AR, Scharnagl H, Muller PY, Mirsaidi R, Stähelin HB, Monsch A, März W, Hoffmann MM. Eur J Clin Invest 33 677-685 (2003)
  245. Independent APOE4 knock-in mouse models display reduced brain APOE protein, altered neuroinflammation, and simplification of dendritic spines. Sepulveda J, Luo N, Nelson M, Ng CAS, Rebeck GW. J Neurochem 163 247-259 (2022)
  246. Interhelical contacts are required for the helix bundle fold of apolipophorin III and its ability to interact with lipoproteins. Wang J, Narayanaswami V, Sykes BD, Ryan RO. Protein Sci 7 336-341 (1998)
  247. Ordered opening of LDL receptor binding domain of human apolipoprotein E3 revealed by hydrogen/deuterium exchange mass spectrometry and fluorescence spectroscopy. Yang L, Hernandez RV, Tran TN, Nirudodhi S, Beck WHJ, Maier CS, Narayanaswami V. Biochim Biophys Acta Proteins Proteom 1866 1165-1173 (2018)
  248. Role of leucine zipper motif in apoE3 N-terminal domain lipid binding activity. Yamamoto T, Ryan RO. Biochim Biophys Acta 1761 1100-1106 (2006)
  249. Semisynthesis and segmental isotope labeling of the apoE3 N-terminal domain using expressed protein ligation. Hauser PS, Raussens V, Yamamoto T, Abdullahi GE, Weers PM, Sykes BD, Ryan RO. J Lipid Res 50 1548-1555 (2009)
  250. Letter A complete backbone assignment of the apolipoprotein E LDL receptor binding domain. Xu C, Sivashanmugam A, Hoyt D, Wang J. J Biomol NMR 32 177 (2005)
  251. Identification of hydropathically complementary putative contact sequences within epidermal growth factor (EGF) and the EGF receptor. Rovati GE, Merli S, Schwarz S. Life Sci 51 37-47 (1992)
  252. Mutation mapping of apolipoprotein A-I structure assisted with the putative cholesterol recognition regions. Dergunov AD. Biochim Biophys Acta 1834 2030-2035 (2013)
  253. Presence of an extended duplication in the putative low-density-lipoprotein receptor-binding domain of apolipoprotein B. Cloning and characterization of the domain in salmon. Babin PJ, Deryckere F, Gannon F. Eur J Biochem 230 45-51 (1995)
  254. Presence of apolipoprotein C-III attenuates apolipoprotein E-mediated cellular uptake of cholesterol-containing lipid particles by HepG2 cells. Morita SY, Sakurai A, Nakano M, Kitagawa S, Handa T. Lipids 46 323-332 (2011)
  255. Structural and phylogenetic approaches to assess the significance of human Apolipoprotein E variation. Corbo RM, Prévost M, Raussens V, Gambina G, Moretto G, Scacchi R. Mol Genet Metab 89 261-269 (2006)
  256. The LDL receptor binding domain of apolipoprotein E directs the relative orientation of its C-terminal segment in reconstituted nascent HDL. Kothari S, Bala N, Patel AB, Donovan A, Narayanaswami V. Biochim Biophys Acta Biomembr 1863 183618 (2021)
  257. apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. Fotakis P, Vezeridis A, Dafnis I, Chroni A, Kardassis D, Zannis VI. J Lipid Res 55 1310-1323 (2014)
  258. An apolipophorin III protein from the hemolymph of desert locust, Schistocerca gregaria. Malik ZA, Amir S. Appl Biochem Biotechnol 165 1779-1788 (2011)
  259. Camellia oil (Camellia oleifera Abel.) treatment improves high-fat diet-induced atherosclerosis in apolipoprotein E (ApoE)-/- mice. Huang T, Jiang J, Cao Y, Huang J, Zhang F, Cui G. Biosci Microbiota Food Health 42 56-64 (2023)
  260. Dynamics of water molecules buried in cavities of apolipoprotein E studied by molecular dynamics simulations and continuum electrostatic calculations. Prévost M. Biopolymers 75 196-207 (2004)
  261. Foam fractionation of a recombinant biosurfactant apolipoprotein. Lethcoe K, Fox CA, Ryan RO. J Biotechnol 343 25-31 (2022)
  262. Profile of Robert W. Mahley. Nuzzo R. Proc Natl Acad Sci U S A 103 5641-5643 (2006)
  263. Structural characterization by computer experiments of the lipid-free LDL-receptor-binding domain of apolipoprotein E. Prévost M, Kocher JP. Protein Eng 12 475-483 (1999)
  264. Structural variation manipulates the differential oxidative susceptibility and conformational stability of apolipoprotein E isoforms. Su KL, Wen TH, Chou CY, Chang GG, Liu GY, Hung HC. Proteins 68 363-374 (2007)
  265. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant. Feussner G, Albanese M, Valencia A. Atherosclerosis 126 177-184 (1996)
  266. Whole Exome Sequencing Reveals a Novel APOE Mutation in a Patient With Sporadic Early-Onset Alzheimer's Disease. Bagaria J, Moon Y, Bagyinszky E, Shim KH, An SSA, Kim S, Han SH. Front Neurol 13 899644 (2022)
  267. Letter Apolipoprotein E Arg136 --> Cys mutation and hyperlipidemia in a large central European population sample. Hubacek JA, Adamková V, Stavek P, Kubinova R, Peasey A, Pikhart H, Marmot M, Bobak M. Clin Chim Acta 388 217-218 (2008)
  268. Bacterial expression and characterization of chicken apolipoprotein A-I. Kiss RS, Kay CM, Ryan RO. Protein Expr Purif 12 353-360 (1998)
  269. Letter Complete 1H, 13C and 15N assignments of a monomeric, biologically active apolipoprotein E carboxyl-terminal domain. Fan D, Korando LA, Dothager RS, Li Q, Wang J. J Biomol NMR 29 419-420 (2004)
  270. Isolation of recombinant apolipoprotein E4 N-terminal domain by foam fractionation. Lethcoe K, Fox CA, Hafiane A, Kiss RS, Ryan RO. Protein Expr Purif 210 106319 (2023)
  271. Native like structure and stability of apo AI in a n-propanol/water solution as determined by 13C NMR. Leroy A, Lippens G, Wieruszeski JM, Parra HJ, Fruchart JC. FEBS Lett 361 29-34 (1995)
  272. Perilipin 3 promotes the formation of membrane domains enriched in diacylglycerol and lipid droplet biogenesis proteins. Khaddaj R, Stribny J, Cottier S, Schneiter R. Front Cell Dev Biol 11 1116491 (2023)
  273. Residues 140-142, 199-200, 222-223, and 262 in the Surface Glycoprotein of Subgroup A Avian Leukosis Virus Are the Key Sites Determining Tva Receptor Binding Affinity and Infectivity. Li J, Chen J, Dong X, Liang C, Guo Y, Chen X, Huang M, Liao M, Cao W. Front Microbiol 13 868377 (2022)
  274. Charged Residues in the C-Terminal Domain of Apolipoprotein A-I Modulate Oligomerization. Fuentes LA, Beck WHJ, Tsujita M, Weers PMM. Biochemistry 57 2200-2210 (2018)
  275. Conformational analysis of apolipoprotein E3/E4 heteromerization. Tu KH, Abhari D, Narayanaswami V. FEBS J 286 1986-1998 (2019)
  276. Molecular modeling of apoE in complexes with Alzheimer's amyloid-β fibrils from human brain suggests a structural basis for apolipoprotein co-deposition with amyloids. Lewkowicz E, Nakamura MN, Rynkiewicz MJ, Gursky O. Cell Mol Life Sci 80 376 (2023)
  277. Orthogonal analysis of variants in APOE gene using in-silico approaches reveals novel disrupting variants. Li C, Hou I, Ma M, Wang G, Bai Y, Liu X. Front Bioinform 3 1122559 (2023)
  278. Resonance assignments and secondary structure of apolipoprotein E C-terminal domain in DHPC micelles. Lo CJ, Chyan CL, Chen YC, Chang CF, Huang HB, Lin TH. Biomol NMR Assign 9 187-190 (2015)


Related citations provided by authors (1)

  1. Crystallization and Preliminary X-Ray Diffraction Studies on the Amino-Terminal (Receptor-Binding) Domain of Human Apolipoprotein E3 from Serum Very Low Density Lipoproteins. Aggerbeck LP, Wetterau JR, Weisgraber KH, Mahley RW, Agard DA J. Mol. Biol. 202 179- (1988)

Quick links